HEART VALVE ALLOGRAFTS NO LONGER REQUIRE PMAS, WILL BE MOVED TO CLASS II; FDA POLICY CHANGE FOLLOWS SETTLEMENT OF LITIGATION WITH TISSUE BANKS
This article was originally published in The Gray Sheet
Executive Summary
Heart valve allografts can be distributed without premarket approval or 510(k) clearance if a processor or distributor marketed the products prior to June 26, 1991, the agency says in a Oct. 14 Federal Register notice announcing that it ceased enforcing premarket approval requirements for heart valve allografts on the same day.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.